Travere Therapeutics (RTRX) Competitors

Zai Lab (NASDAQ:ZLAB) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.

Which has preferable valuation and earnings, ZLAB or RTRX?

Travere Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$398.99M	8.60	-$334.62M	-$2.59	-12.03
Travere Therapeutics	$175.34M	6.06	-$146.43M	-$3.46	-6.01

Is ZLAB or RTRX more profitable?

Travere Therapeutics has a net margin of -49.13% compared to Zai Lab's net margin of -76.14%. Travere Therapeutics' return on equity of -36.38% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-76.14%	-36.97%	-27.10%
Travere Therapeutics	-49.13%	-36.38%	-14.90%

Do analysts recommend ZLAB or RTRX?

Zai Lab presently has a consensus price target of $47.37, suggesting a potential upside of 52.06%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts plainly believe Zai Lab is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Travere Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility & risk, ZLAB or RTRX?

Zai Lab has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Do insiders and institutionals believe in ZLAB or RTRX?

41.7% of Zai Lab shares are held by institutional investors. 13.9% of Zai Lab shares are held by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media prefer ZLAB or RTRX?

In the previous week, Zai Lab had 12 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Zai Lab and 0 mentions for Travere Therapeutics. Zai Lab's average media sentiment score of 0.76 beat Travere Therapeutics' score of 0.00 indicating that Zai Lab is being referred to more favorably in the media.

Company	Overall Sentiment
Zai Lab	Positive
Travere Therapeutics	Neutral

Does the MarketBeat Community prefer ZLAB or RTRX?

Travere Therapeutics received 189 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 73.17% of users gave Travere Therapeutics an outperform vote while only 64.53% of users gave Zai Lab an outperform vote.

Company	Underperform	Outperform
Zai Lab	Outperform Votes 231 64.53%	Underperform Votes 127 35.47%
Travere Therapeutics	Outperform Votes 420 73.17%	Underperform Votes 154 26.83%

Summary

Zai Lab beats Travere Therapeutics on 11 of the 18 factors compared between the two stocks.